A. Oliver Sartor, MD

Oliver Sartor, MD, discusses updated efficacy findings from the phase 3 PSMAfore trial of lutetium Lu 177 vipivotide tetraxetan in patients with previously treated, taxane-naive metastatic castration-resistant prostate cancer.

Highlighting ongoing clinical trials in prostate cancer, experts share practical advice on optimal treatment strategies for community physicians.

Oliver Sartor, MD, discusses the significance of the REASSURE trial in patients with metastatic castration-resistant prostate cancer.

A. Oliver Sartor, MD, discusses the design of the REASSURE trial (NCT02141438) in patients with metastatic castration-resistant prostate cancer.

A. Oliver Sartor, MD, discusses the rationale for investigating the sequential use of beta emitters and alpha emitters in metastatic castration-resistant prostate cancer.

A. Oliver Sartor, MD, discusses the implications of prostate-specific membrane antigen-PET positivity in prostate cancer.

A. Oliver Sartor, MD, professor of medicine, medical director, Tulane Cancer Center, and C. E. and Bernadine Laborde Professor of Cancer Research, Departments of Medicine and Urology, Tulane University, discusses emerging agents in prostate cancer.

A. Oliver Sartor, MD, discusses research on immunotherapy, radiopharmaceuticals, and combinations in prostate cancer.

A. Oliver Sartor, MD, discusses the phase III VISION trial in patients with prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer.